Cell & Gene Therapy Addressing analytical control challenges for different plasmid DNA products 11-30-2022 / Lauren Lu, Senior Director of QC Dept Addressing analytical control challenges for different plasmid DNA products Learn More
Cell & Gene Therapy Development and manufacturing Strategy for DNA Base Vaccine-Drug Candidates 11-01-2022 / Mark Wei Since the outbreaks of COVID-19, DNA vaccines are promising in the SARS-CoV-2 vaccine race although they have a new platform technology that was not previously available on the market for human use. Learn More
Cell & Gene Therapy Scalable AAV Manufacturing Strategies 07-14-2022 / Dr. Xiao Pan Since the approval of the product Luxtura® using AAV as a vector in 2017, more and more clinical trials have been carried out rapidly, and various early clinical trial projects for rare diseases and a wide range of indications .. Learn More
Cell & Gene Therapy Lentiviral vector manufacturing using suspension cell line 03-11-2021 / Dr. Mahmood Ali, Project Manager of Virus (R&D) Purification Process CGT has made a great breakthrough in the recent years, however the industry is facing challenges in developing stable and scalable manufacturing process for viral vectors. Learn More
Cell & Gene Therapy How to improve plasmid and viral vector manufacturing process 11-26-2020 / Shigang Wei, Director of Plasmid & Virus Process Development Department As more CGT products are in clinical phases, demand for large-scale lentiviral vector manufacturing and implementation of suspension system are increasing. GenScript ProBio is dedicated to improving technologies and product quality to me Learn More